Newsletter Subscribe
Enter your email address below and subscribe to our newsletter
Enter your email address below and subscribe to our newsletter

Sight Sciences released study findings demonstrating that patients with glaucoma who had undergone procedures using their OMNI Surgical System technology had a greater average reduction in the usage of intraocular pressure-lowering medication compared to those who had received only minimally…

Belkin Vision has received FDA 510(k) clearance for its Eagle device, a Q-switched, 532 nm-wavelength, frequency-doubled Nd:YAG laser developed for selective laser trabeculoplasty (SLT). The Eagle is positioned by Belkin as the first and only contactless laser for glaucoma, offering…

Keratoprosthesis refers to an innovative surgical procedure designed to restore vision in individuals suffering from severe corneal disease or damage. The term ‘keratoprosthesis’ is derived from the Greek words ‘kerato,’ meaning cornea, and ‘prosthesis,’ meaning artificial addition. The cornea, being…

Carl Zeiss Meditec AG announced that they have entered into an agreement to acquire 100% of the shares in D.O.R.C. Dutch Ophthalmic Research Center (International) B.V. from Eurazeo SE, based in Paris, France. The deal is worth €985 million (nearly…

Sight Sciences expressed its support for the decision made by five Medicare Administrative Contractors to withdraw their previously announced final local coverage determinations (LCDs) for Micro-Invasive Glaucoma Surgery, originally slated to become effective on January 29, 2024. The five MACs—WPS…

Laser eye surgery has become a popular solution for correcting vision problems such as nearsightedness, farsightedness, and astigmatism. While the procedure is known for its high success rate and quick recovery times, proper post-operative care is crucial to achieve optimal…

LEP Biomedical announced pre-seed funding of €100,000 ($107,000) over two 6-month periods, which the company says will allow for further preclinical milestones in the development of the HyaGuard platform. The funding was made through Enterprise Ireland. Innovative Design of HyaGuard…

Ocugen has officially completed dosing in the second cohort of its phase 1/2 ArMaDa trial of OCU410, a novel gene therapy designed to treat geographic atrophy (GA). The therapy, known as adeno-associated viral vector 5 human RORA (AAV5-hRORA), is being…

In a recent paper published in the journal Eye, Canadian researchers have evaluated the capabilities of two artificial intelligence chatbots, Google Gemini and Bard, in the ophthalmology board examination. They found that both AI tools achieved acceptable accuracy levels and…

In an inspiring leap towards health equity, a new eye health project in Malawi has successfully brought essential services to the grassroots level. This initiative, supported by Sightsavers, has notably reached over 122,000 individuals in rural and economically disadvantaged areas…